International Journal of Hematology

, Volume 91, Issue 5, pp 826–830

A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center

  • Joen Chiang
  • Alexandre Chan
  • Vivianne Shih
  • Siew Wan Hee
  • Miriam Tao
  • Soon Thye Lim
Original Article

Abstract

Rituximab (Mabthera®) is currently approved for the treatment of multiple subtypes of CD20-expressing, B-cell, non-Hodgkin’s lymphoma. This study aimed to investigate whether rapid infusion of rituximab over 90 min is feasible without compromising patient’s safety, and to reduce resource utilization at a cancer center. This is a prospective and open label study. Lymphoma patients who have received one cycle of rituximab without experiencing grade 3 or 4 infusional reaction were eligible for the rapid infusion of rituximab. Rapid infusion rituximab is infused over 90 min, with 20% of the dose given over the first 30 min and the remaining 80% over 60 min. A total of 79 patients were recruited for this study with a total of 269 infusions administered. Sixty-nine patients (87.3%) received rituximab in combination with chemotherapy. Average number of rituximab infusions administered to patients was 3.4 cycles. Rapid rituximab infusion schedule was well tolerated without any grade 3/4 infusion-related adverse events observed. An average amount of time saved per patient was 10.2 h. Rapid infusion rituximab over 90 min was well tolerated by patients, and shortened infusions have resulted in substantial reduction of resource utilization.

Keywords

Rituximab Rapid infusion Resource utilization 

References

  1. 1.
    National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Non-Hodgkin’s Lymphomas. Version 1.2010.Google Scholar
  2. 2.
    Rituximab (Rituxan). South San Francisco: Genetech Inc. 2008.Google Scholar
  3. 3.
    Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, et al. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol. 2006;77(4):338–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 2007;109(10):4171–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Gibbs S, Pout G, Wimperis J. Rapid infusion rituximab is as effective and safe as conventional infusion regimes in the treatment of diffuse large B cell lymphoma: a 2 year prospective study. Haematologica. 2007;92(Suppl. 2):264.Google Scholar
  6. 6.
    Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103:4416–23.Google Scholar
  7. 7.
    Tuthill M, Crook T, Corbet T, King J, Webb A. Rapid infusion of rituximab over 60 min. Eur J Haematol. 2009;82(4):322–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Provencio M, Cerdeira S, Bonilla F, Sanchez A, Espana P. Rapid infusion rituximab in lymphoma treatment. Ann Oncol. 2006;17(6):1027–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Siano M, Lerch E, Negretti L, Zucca E, Rodriguez-Abreu D, et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res. 2008;14(23):7935–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Joen Chiang
    • 1
  • Alexandre Chan
    • 1
    • 2
  • Vivianne Shih
    • 1
  • Siew Wan Hee
    • 3
  • Miriam Tao
    • 4
  • Soon Thye Lim
    • 4
  1. 1.Department of PharmacyNational Cancer Centre SingaporeSingaporeSingapore
  2. 2.Department of Pharmacy, Faculty of ScienceNational University of SingaporeSingaporeSingapore
  3. 3.Division of Clinical Trials and Epidemiological SciencesNational Cancer Centre SingaporeSingaporeSingapore
  4. 4.Department of Medical OncologyNational Cancer Centre SingaporeSingaporeSingapore

Personalised recommendations